Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1B/2A Study to Assess the Safety, Tolerability, Pharmacokinetic and Anti-tumoral Activity of EXS21546 in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours

Next Previous
Trial Profile

A Phase 1B/2A Study to Assess the Safety, Tolerability, Pharmacokinetic and Anti-tumoral Activity of EXS21546 in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 26 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EXS 21546 (Primary) ; Nivolumab (Primary)
  • Indications Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms IGNITE; IGNITE-AI
  • Sponsors Exscientia

Most Recent Events

  • 06 Nov 2023 Status changed from recruiting to discontinued.
  • 03 Oct 2023 According to an Exscientia media release, based on modelling of the clinical and preclinical data, it will be challenging for EXS-546 to reach a suitable therapeutic index therefore company has decided to wound down this Phase 1/2 trial and discontinue internal research around the target.
  • 24 May 2023 According to an Exscientia media release, in May 2023 first patient was dosed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top